Detalhe da pesquisa
1.
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).
Br J Cancer
; 130(2): 224-232, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37973958
2.
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.
Oncologist
; 29(6): e741-e749, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38340010
3.
The emerging emetogenicity of trifluridine/tipiracil (TAS102) from patient self-reporting: a multicenter, prospective, observational study.
Support Care Cancer
; 32(5): 291, 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630197
4.
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.
Int J Clin Oncol
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38753042
5.
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023.
Int J Clin Oncol
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38722486
6.
Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias.
BMC Cancer
; 23(1): 1078, 2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37940878
7.
Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study.
Support Care Cancer
; 31(12): 657, 2023 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37884842
8.
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Support Care Cancer
; 32(1): 45, 2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114821
9.
One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis.
Oncologist
; 27(6): e524-e532, 2022 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35427418
10.
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
BMC Cancer
; 22(1): 310, 2022 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35321690
11.
5HT3 RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer.
Cancer Sci
; 112(2): 744-750, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33274555
12.
Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.
Oncologist
; 26(6): e1066-e1072, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33811782
13.
Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
BMC Cancer
; 21(1): 74, 2021 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451299
14.
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.
BMC Cancer
; 21(1): 832, 2021 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34281514
15.
Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib.
Int J Clin Oncol
; 26(7): 1257-1263, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33839963
16.
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.
Int J Clin Oncol
; 26(1): 1-17, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33161452
17.
A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
Oncologist
; 25(2): e373-e380, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043774
18.
Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Oncologist
; 25(3): e469-e476, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162797
19.
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Gynecol Oncol
; 156(3): 629-635, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31926638
20.
Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy.
Support Care Cancer
; 28(12): 5943-5952, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32281034